Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.

Mechanism / theoretical grounding — not clinical validation.

Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Int J Mol Sci. 2022.

Organ: general-aging · Type: theoretical · Peptides: Vilon, Epitalon, KED

An open-access IJMS review using molecular modeling to argue that POT and LAT carriers can move ultrashort di- and tripeptides into tissue cells — a transport hypothesis, not a clinical trial.

Editorial summary of a 2022 International Journal of Molecular Sciences article (MDPI, open access: doi:10.3390/ijms23147733). Modeling and literature synthesis of peptide transporters. Public pages cite PubMed; the DOI is the OA record. Read the paper: PMID 35887081.

Methods

The authors survey published work on ultrashort peptides (2–7 residues) and on POT-family carriers (PEPT1, PEPT2, PHT1, PHT2) and LAT transporters under normal, pathological, and ageing conditions. They cite molecular modeling and physicochemistry for LAT1’s possible transfer of some di- and tripeptides as well as amino acids. No new patient cohort is reported.

Findings

POT carriers are described as moving predominantly di- and tripeptides into the cell. The authors conclude that, depending on structure, di- and tripeptides can be transported into cells of various tissues by POT and LAT transporters, and they propose that this may underlie tissue specificity, geroprotective claims, and effects discussed in neuroimmunoendocrine disorders.

That is a transporter hypothesis built from modeling and prior papers. It is not evidence of clinical benefit for Vilon, Epitalon, KED, or any other ultrashort peptide. Follow the PMID and the OA DOI.